Therapeutic drug monitoring in CML patients on imatinib
- 1 September 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (5) , 1699-1701
- https://doi.org/10.1182/blood-2007-03-079871
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006
- Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.Blood, 2006
- Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia PatientsJournal of Clinical Oncology, 2004
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001